期刊
PULMONOLOGY
卷 24, 期 3, 页码 170-173出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.rppnen.2017.10.001
关键词
Pulmonary arterial hypertension; Macitentan; Endothelin-receptor antagonist; Clinical practice; Phosphodiesterase 5 inhibitors; Prostaglandins
资金
- Actelion Spain
The effectiveness and safety of macitentan, a dual endothelin-receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH), were shown in an extensive clinical trial oriented towards morbidity and mortality events. Our aim was to describe a single centre's experience of the utilization of macitentan in patients with PAH in clinical practice settings. Thirteen patients with different aetiologies and previous PAH treatments were studied. After 12 months of macitentan treatment, 11 patients improved their functional class (FC), all patients improved their 6-minute walk distance (6MWD) test, and 10 patients lowered their NT-proBNP plasma levels. Additionally, cardiac imaging parameters were also improved. No cases resulted in hospitalization, septostomy, transplant or death. (C) 2017 Sociedade Portuguesa de Pneumologia. Published by Elsevier Espana, S.L.U.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据